How 'place' matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa.
Communities
Community randomised trials (CRTs)
Social context
Southern Africa
Stability
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
06 Apr 2021
06 Apr 2021
Historique:
received:
29
04
2020
accepted:
16
03
2021
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
22
6
2021
Statut:
epublish
Résumé
In a cluster-randomised trial (CRT) of combination HIV prevention (HPTN 071 (PopART)) in 12 Zambian communities and nine South African communities, carried out from 2012 to 2018, the intervention arm A that offered HIV treatment irrespective of CD4 count did not have a significant impact on population level HIV incidence. Intervention arm B, where HIV incidence was reduced by 30%, followed national guidelines that mid trial (2016) changed from starting HIV treatment according to a CD4 threshold of 500 to universal treatment. Using social science data on the 21 communities, we consider how place (community context) might have influenced the primary outcome result. A social science component documented longitudinally the context of trial communities. Data were collected through rapid qualitative assessment, interviews, group discussions and observations. There were a total of 1547 participants and 1127 observations. Using these data, literature and a series of qualitative analysis steps, we identified key community characteristics of relevance to HIV and triangulated these with HIV community level incidence. Two interdependent social factors were relevant to communities' capability to manage HIV: stability/instability and responsiveness/resistance. Key components of stability were social cohesion; limited social change; a vibrant local economy; better health, education and recreational services; strong institutional presence; established middle-class residents; predictable mobility; and less poverty and crime. Key components of responsiveness were community leadership being open to change, stronger history of HIV initiatives, willingness to take up HIV services, less HIV-related stigma and a supported and enterprising youth population. There was a clear pattern of social factors across arms. Intervention arm A communities were notably more resistant and unstable. Intervention arm B communities were overall more responsive and stable. In the specific case of the dissonant primary outcome results from the HPTN 071 (PopART) trial, the chance allocation of less stable, less responsive communities to arm A compared to arm B may explain some of the apparently smaller impact of the intervention in arm A. Stability and responsiveness appear to be two key social factors that may be relevant to secular trends in HIV incidence. We advocate for a systematic approach, using these factors as a framework, to community context in CRTs and monitoring HIV prevention efforts. ClinicalTrials.gov NCT01900977 . Registered on July 17, 2013.
Sections du résumé
BACKGROUND
BACKGROUND
In a cluster-randomised trial (CRT) of combination HIV prevention (HPTN 071 (PopART)) in 12 Zambian communities and nine South African communities, carried out from 2012 to 2018, the intervention arm A that offered HIV treatment irrespective of CD4 count did not have a significant impact on population level HIV incidence. Intervention arm B, where HIV incidence was reduced by 30%, followed national guidelines that mid trial (2016) changed from starting HIV treatment according to a CD4 threshold of 500 to universal treatment. Using social science data on the 21 communities, we consider how place (community context) might have influenced the primary outcome result.
METHODS
METHODS
A social science component documented longitudinally the context of trial communities. Data were collected through rapid qualitative assessment, interviews, group discussions and observations. There were a total of 1547 participants and 1127 observations. Using these data, literature and a series of qualitative analysis steps, we identified key community characteristics of relevance to HIV and triangulated these with HIV community level incidence.
RESULTS
RESULTS
Two interdependent social factors were relevant to communities' capability to manage HIV: stability/instability and responsiveness/resistance. Key components of stability were social cohesion; limited social change; a vibrant local economy; better health, education and recreational services; strong institutional presence; established middle-class residents; predictable mobility; and less poverty and crime. Key components of responsiveness were community leadership being open to change, stronger history of HIV initiatives, willingness to take up HIV services, less HIV-related stigma and a supported and enterprising youth population. There was a clear pattern of social factors across arms. Intervention arm A communities were notably more resistant and unstable. Intervention arm B communities were overall more responsive and stable.
CONCLUSIONS
CONCLUSIONS
In the specific case of the dissonant primary outcome results from the HPTN 071 (PopART) trial, the chance allocation of less stable, less responsive communities to arm A compared to arm B may explain some of the apparently smaller impact of the intervention in arm A. Stability and responsiveness appear to be two key social factors that may be relevant to secular trends in HIV incidence. We advocate for a systematic approach, using these factors as a framework, to community context in CRTs and monitoring HIV prevention efforts.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT01900977 . Registered on July 17, 2013.
Identifiants
pubmed: 33823907
doi: 10.1186/s13063-021-05198-5
pii: 10.1186/s13063-021-05198-5
pmc: PMC8025534
doi:
Banques de données
ClinicalTrials.gov
['NCT01900977']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
251Subventions
Organisme : Department for International Development
ID : 00
Organisme : U.S. President's Emergency Plan for AIDS Relief
ID : 00
Organisme : National Institute of Allergy and Infectious Diseases
ID : UMq-AI068617
Organisme : NIAID NIH HHS
ID : U01 AI068617
Pays : United States
Organisme : Bill and Melinda Gates Foundation
ID : 00
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Références
BMJ Glob Health. 2019 Jun 18;4(3):e001746
pubmed: 31297249
J Int AIDS Soc. 2018 Oct;21 Suppl 7:e25173
pubmed: 30334379
Lancet Infect Dis. 2004 May;4(5):267-77
pubmed: 15120343
PLoS One. 2014 Jan 31;9(1):e87527
pubmed: 24498125
Lancet. 2016 Jun 11;387(10036):2423-78
pubmed: 27174304
Prev Med. 2018 Mar;108:17-22
pubmed: 29288780
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
AIDS. 2018 Mar 27;32(6):783-793
pubmed: 29369164
Trials. 2014 Feb 13;15:57
pubmed: 24524229
Qual Health Res. 2019 Apr;29(5):700-718
pubmed: 30556470
Lancet Infect Dis. 2004 Jun;4(6):368-75
pubmed: 15172345
Trop Med Int Health. 2002 Jun;7(6):489-98
pubmed: 12031070
AIDS Patient Care STDS. 2016 Sep;30(9):425-34
pubmed: 27610464
Pilot Feasibility Stud. 2015 Sep 7;1:32
pubmed: 27965810
PLoS Med. 2007 Mar 27;4(3):e102
pubmed: 17388666
Implement Sci. 2017 Feb 15;12(1):21
pubmed: 28202031
J Urban Health. 2012 Feb;89(1):19-35
pubmed: 22131164
N Engl J Med. 2019 Jul 18;381(3):286-288
pubmed: 31314975
PLoS Med. 2012;9(7):e1001250
pubmed: 22807657
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25117
pubmed: 30027643
Trials. 2012 Jun 28;13:95
pubmed: 22742939
Trials. 2019 Jun 6;20(1):329
pubmed: 31171041
BMJ. 2006 Feb 18;332(7538):413-6
pubmed: 16484270
Soc Sci Med. 2015 Aug;138:265-8
pubmed: 26032734
AIDS Care. 2016;28 Suppl 3:99-107
pubmed: 27421057
N Engl J Med. 2019 Jul 18;381(3):219-229
pubmed: 31314966
Health Place. 2015 Nov;36:127-33
pubmed: 26513597
Med Anthropol Q. 2003 Dec;17(4):423-41
pubmed: 14716917
AIDS. 2017 Jul 01;31 Suppl 3:S221-S232
pubmed: 28665880
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25136
pubmed: 30027588
AIDS Patient Care STDS. 2020 Jan;34(1):38-50
pubmed: 31944852
Health Policy Plan. 2016 Dec;31(10):1342-1354
pubmed: 27375126
PLoS Med. 2019 May 31;16(5):e1002811
pubmed: 31150380
Curr HIV/AIDS Rep. 2016 Aug;13(4):194-201
pubmed: 27405816
PLoS Med. 2019 May 21;16(5):e1002808
pubmed: 31112543
PLoS Med. 2019 May 21;16(5):e1002809
pubmed: 31112546